NANOFÁRMACOS

VolverVolver

Resultados 177 resultados LastUpdate Última actualización 17/05/2021 [18:10:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 8 nextPage   por página


一种用于靶向药物递送的磁场场控螺旋纳米机器人

NºPublicación: CN112791064A 14/05/2021

Solicitante:

清华大学

Resumen de: CN112791064A

本发明提出了一种用于靶向药物递送的磁场场控螺旋纳米机器人,所述纳米机器人包括螺旋碳纳米管基体、聚乙二醇修饰层、磁性纳米载药颗粒、靶细胞配体。本发明的螺旋纳米机器人可实现磁场驱动、药物搭载、靶向细胞识别、可控药物释放、荧光反馈等多种功能,为药物递送的科学研究和临床治疗奠定基础,在生物医学领域具有潜在的应用前景。

traducir

一种具有长循环性纳米药物载体的制备方法及应用

NºPublicación: CN112791065A 14/05/2021

Solicitante:

西安工程大学

Resumen de: CN112791065A

本发明公开了一种具有长循环性纳米药物载体的制备方法,具体为:首先,甲醛和壳聚糖上的氨基形成希弗氏碱,然后聚乙二醇单甲醚上的羟基和希弗氏碱发生加成反应生成聚乙二醇单甲醚接枝壳聚糖;利用NIPAm和AMPS自由基聚合制备聚阴离子PNAM;以CS‑g‑mPEG作为聚阳离子,以PNAM作为聚阴离子,通过聚电解质复合法制备具有长循环性纳米药物载体。本发明制备的纳米药物载体不仅具备壳聚糖的可生物降解性、无毒性和低免疫原性以及抑菌抗癌等优势,还具有聚乙二醇良好的生物相容性以及在血液中的长循环性,提高了小分子化疗药物对癌细胞的选择性,减少了用药次数,降低了对正常组织与细胞的损害,提高了药物的生物利用率。

traducir

PHARMACEUTICAL COMPOSITIONS COMPRISING STABLE AMORPHOUS HYBRID NANOPARTICLES COMPRISING AT LEAST ONE PROTEIN KINASE INHIBITOR AND AT LEAST ONE POLYMERIC STABILIZING AND MATRIX-FORMING COMPONENT

NºPublicación: JP2021073228A 13/05/2021

Solicitante:

エックススプレイファーマパブリーク・アクチエボラグXSprayPharmaAB(publ)

MX_371349_B

Resumen de: JP2019070000A

To provide novel pharmaceutical compositions comprising a poorly water-soluble drug, which are capable of improving bioavailability and stability of the pharmacologically active ingredient.SOLUTION: Disclosed herein is a pharmaceutical composition comprising stable amorphous solid dispersion particles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming ingredient, which composition may optionally further comprises at least one pharmaceutically acceptable solubilizer. The invention also encompasses stable amorphous solid dispersion particles containing at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming ingredient.SELECTED DRAWING: None

traducir

BIOORTHOGONAL COMPOSITIONS

NºPublicación: JP2021073200A 13/05/2021

Solicitante:

タンボ・インコーポレイテッド

US_2021015932_A1

Resumen de: WO2017044983A1

The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing the compositions, as well as methods of using the same.

traducir

Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases

NºPublicación: AU2021202374A1 13/05/2021

Solicitante:

DISTRETTO TECNOLOGICO SICILIA MICRO E NANO SISTEMI S C A R L

US_2021046083_A1

Resumen de: AU2021202374A1

Formulations are described, containing silibinin or other active ingredients incorporated in lipid nanoparticle systems of the SLN and NLC type, and based on calixarenes, possibly mucoadhesive, or in micellar and nanoparticle systems based on amphiphilic inulin copolymers for use in the treatment of neurodegenerative ocular diseases. The versatility of the calixarene compound is also described, capable of charging and releasing active ingredients characterized by low water solubility, easy chemical and enzymatic degradation, low bioavailability, either of natural origin or not, to be used in the treatment of ocular diseases.

traducir

IONIZABLE CATIONIC LIPID FOR RNA DELIVERY

NºPublicación: JP2021073263A 13/05/2021

Solicitante:

アークトゥルスセラピューティクス,インコーポレイテッド

AU_2021200663_A1

Resumen de: WO2018118102A1

What is described is a compound of formula (I) consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons; L1 and L2 are the same or different, each a linear alkylene of 1 to 20 carbons or a linear alkenylene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

traducir

Small highly uniform nanomedicine compositions for therapeutic, imaging and theranostic applications

NºPublicación: AU2019337699A1 13/05/2021

Solicitante:

UNIV MICHIGAN REGENTS

CA_3112787_A1

Resumen de: AU2019337699A1

A targetable nanoconstruct capable of simultaneously serving as a therapeutic platform for photodynamic therapy as well as an MR molecular imaging agent, free of heavy metal atoms. F3-cys targeting agent nanoconstructs, including 8PEGA-Ce6 NCs. A label-free 8PEGA nanoconstruct that can be directly and selectively imaged by MRI, using standard spin-echo imaging sequences with large diffusion magnetic field gradients to suppress the water signal.

traducir

COMPOSITION FOR ORAL DELIVERY OF SORAFENIB AND USE OF SAID COMPOSITION

NºPublicación: JPWO2019208617A1 13/05/2021

Solicitante:

国立大学法人筑波大学国立大学法人旭川医科大学

WO_2019208617_PA

Resumen de: WO2019208617A1

[Problem] To provide a pharmaceutical composition effective in fibrosis. [Solution] Provided is: a composition containing a copolymer that includes a sorafenib and poly(ethylene glycol) segment, as well as a segment based on polystyrene having a cyclic nitroxide radical and a tri(alkoxysilane) each randomly in a side chain, the copolymer optionally containing a tetra(alkoxy)silane; or nanoparticles formed from said composition.

traducir

PREVENTION OF MUSCULAR DYSTROPHY BY CRISPR/CAS9-MEDIATED GENE EDITING

NºPublicación: JP2021073304A 13/05/2021

Solicitante:

ザボードオブリージェンツオブザユニバーシティーオブテキサスシステム

JP_2017525696_A

Resumen de: WO2016025469A1

Duchenne muscular dystrophy (DMD) is an inherited X-linked disease caused by mutations in the gene encoding dystrophin, a protein required for muscle fiber integrity. The disclosure reports CRISPR/Cas9-mediated gene editing (Myo-editing) is effective at correcting the dystrophin gene mutation in the mdx mice, a model for DMD. Further, the disclosure reports optimization of germline editing of mdx mice by engineering the permanent skipping of mutant exon (exon 23) and extending exon skipping to also correct the disease by post-natal delivery of adeno-associate virus (AAV). AAV-mediated Myo-editing can efficiently rescue the reading frame of dystrophin in mdx mice in vivo. The disclosure reports means of Myo-editing-mediated exon skipping has been successfully advanced from somatic tissues in mice to human DMD patients-derived iPSCs (induced pluripotent stem cells). Custom Myo-editing was performed on iPSCs from patients with differing mutations and successfully restored dystrophin protein expression for all mutations in iPSCs-derived cardiomyocytes.

traducir

ALTERING INFLAMMATORY STATES OF IMMUNE CELLS IN VIVO BY MODULATING CELLULAR ACTIVATION STATES

NºPublicación: JP2021512056A 13/05/2021

Solicitante:

フレッドハッチンソンキャンサーリサーチセンター

US_2021046156_A1

Resumen de: WO2019143948A1

Systems and methods to modulate the activation state of immune cells in vivo are described. The systems and methods can be used to transform immunosuppressive macrophages that support cancer growth and metastasis into highly activated tumoricidal macrophages.

traducir

TOLEROGENIC SYNTHETIC NANOCARRIERS AND THERAPEUTIC MACROMOLECULES FOR REDUCED OR ENHANCED PHARMACODYNAMIC EFFECTS

NºPublicación: JP2021073198A 13/05/2021

Solicitante:

セレクタバイオサイエンシーズインコーポレーテッドSELECTABIOSCIENCES,INC.

US_2020360350_A1

Resumen de: AU2020200065A1

Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.

traducir

Injectable long-acting naltrexone microparticle compositions

NºPublicación: AU2019362730A1 13/05/2021

Solicitante:

CHONG KUN DANG PHARMACEUTICAL CORP
PURDUE RESEARCH FOUNDATION

CA_3112938_PA

Resumen de: AU2019362730A1

The present disclosure relates to naltrexone sustained release microparticle delivery systems for the treatment of diseases ameliorated by naltrexone. The injectable microparticle delivery system includes naltrexone encapsulated in biodegradable microparticles administered in a pharmaceutically acceptable vehicle.

traducir

COMPOSITIONS AND METHODS OF TREATMENT

NºPublicación: EP3817729A1 12/05/2021

Solicitante:

BLUEBERRY THERAPEUTICS LTD [GB]

CN_112770732_A

Resumen de: WO2020008195A1

The present invention relates to compositions for use in the treatment of a dermatological condition, comprising a polymer capable of forming nanoparticles an anti-inflammatory and/or analgesic agent. The composition is particularly suited to the treatment of acne and/or atopic dermatitis. The invention also relates to novel uses of polyhexamethylene biguanide.

traducir

COMPOSITIONS AND METHODS OF TREATMENT

NºPublicación: EP3817730A1 12/05/2021

Solicitante:

BLUEBERRY THERAPEUTICS LTD [GB]

CN_112752571_A

Resumen de: WO2020008196A1

The present invention relates to compositions for use in the treatment or management of inflammation and/or pain, comprising a polymer capable of forming nanoparticles an anti-inflammatory and/or analgesic agent. The invention also relates to novel uses of polyhexamethylene biguanide.

traducir

STRUCTURE

NºPublicación: EP3818976A1 12/05/2021

Solicitante:

NITTO DENKO CORP [JP]

BR_112020025315_A2

Resumen de: EP3818976A1

The present invention provides a structure suitable for controlling the release quantity of an active ingredient in a state where the structure is in contact with skin. A structure 10 according to the present invention includes a retention part 1 that retains an active ingredient, and a release control layer 3 that controls release of the active ingredient to an outside. In the structure 10, at least one of the following conditions holds: i) the release control layer 3 includes a microporous membrane having an average pore diameter of 0.01 µm or less; and ii) the release control layer 3 is a nanofiltration membrane or a reverse osmotic membrane.

traducir

METHOD FOR PREPARING COMPOSITE FOR ENHANCING IMMUNE RESPONSE

NºPublicación: EP3818990A1 12/05/2021

Solicitante:

XINFU BEIJING MEDICAL TECH CO LTD [CN]

KR_20210025095_PA

Resumen de: EP3818990A1

A novel composite, and research on the preparation, application and the like of the composite. The method for preparing the composite comprises: contacting a polyinosinic-polycytidylic acid, at least one cationic stabilizer, and a soluble calcium salt in a liquid reaction system, the cationic stabilizer being a water-soluble non-antibiotic amino compound having a molecular weight of less than or equal to 5 kDa, or a graft copolymer formed by a water-soluble non-antibiotic amino compound and one or more of methoxypolyethylene glycol, polyethylene glycol, polyethylenimine, folic acid, or galactose. The composite has moderate viscosity and molecular weight, is convenient to use in pharmaceutical application, has stable chemical properties, is not easy to be degraded in long-term storage, and is safe to use. The composite, if used alone, can significantly enhance the non-specific immune response of the body and achieve the purpose of preventing and treating diseases, and other drugs, and can achieve better anti-tumor, anti-viral and anti-(super) bacteria efficacy and is easily absorbed by patients, if used in combination with other drugs.

traducir

一种cRGD-DFX-BSA-NPS纳米粒子及其制备方法和应用

NºPublicación: CN112773777A 11/05/2021

Solicitante:

中国科学院长春应用化学研究所

Resumen de: CN112773777A

本发明公开了一种cRGD‑DFX‑BSA‑NPS纳米粒子及其制备方法和应用,属于医药领域。该粒子制备方法包括:步骤一:cRGD‑BSA粒子的合成;步骤二:cRGD‑DFX‑BSA‑NPS纳米粒子的合成;本发明还提供了根据该制备方法得到的cRGD‑DFX‑BSA‑NPS纳米粒子以及该粒子作为药物在肿瘤区域响应性释放的应用。DFX纳米颗粒制剂在制备的过程中加入了GSH响应的分子,使得纳米粒子能够在肿瘤环境下有效的释放DFX。

traducir

一种基于牛血清白蛋白的短波红外荧光金纳米簇及其制备方法与应用

NºPublicación: CN112775432A 11/05/2021

Solicitante:

武汉大学苏州研究院

Resumen de: CN112775432A

本发明公开了一种基于牛血清白蛋白的短波红外荧光金纳米簇及其制备方法与应用。以氯金酸为原料,通过牛血清白蛋白上的赖氨酸和组氨酸与Au3+的配位,以及利用溶液pH>10时牛血清白蛋白上的酪氨酸和硼氢化钠对Au3+的还原性以形成金纳米簇(BSA@AuNCs),该制备方法简单,反应条件温和,制备的BSA@AuNCs粒径小于2 nm,具有良好的水溶性和稳定性,光稳定性好,荧光量子产率高,生物相容性好。此外,本发明所合成的BSA@AuNCs在808 nm激光辐射下可产生活性氧,可用于肿瘤光动力治疗;其最大荧光发射峰约为915 nm,可用于肿瘤的短波红外荧光成像,具有极好的应用前景。

traducir

NANOPARTICLE COMPOSITIONS

NºPublicación: CN112789057A 11/05/2021

Solicitante:

詹纽瑞治疗公司

Resumen de: WO2020023549A1

Provided herein are nanoparticle compositions comprising a pharmaceutically acceptable carrier and a compound of Formula (I): A-L-B.

traducir

一种载药纳米粒体系

NºPublicación: CN112773776A 11/05/2021

Solicitante:

上海胜联医药科技有限公司

Resumen de: CN112773776A

一种载药纳米粒体系,用于直接添加不同种类的醇溶性药物,体系中的载药纳米粒融合醇溶性药物后成为含药纳米粒,其原料包括亲脂性表面活性剂、亲水性表面活性剂和水;亲脂性表面活性剂和亲水性表面活性剂的质量比为0.10∶9.90‑9.99∶0.01;所有表面活性剂总量和水的质量比为0.10∶99.9‑20∶80;将亲脂性表面活性剂和亲水性表面活性剂加入水溶液混合搅拌后自激发、自组装形成载药纳米粒体系,其中载药纳米粒的粒径大小为5‑300nm。本发明的载药纳米粒,能直接添加不同种类的醇溶性药物,空白载药纳米粒可融合药物成为含药纳米粒,结构稳定,包封率及载药效率高。

traducir

一种纳米反应器及其制备方法和应用

NºPublicación: CN112773895A 11/05/2021

Solicitante:

湖南省人民医院

Resumen de: CN112773895A

本发明公开了一一种纳米反应器及其制备方法和应用,所述纳米反应器包括核壳纳米粒和层层包裹在所述核壳纳米粒表面的二氧化锰和靶向配体;所述核壳纳米粒由金属有机框架、光敏剂、葡萄糖氧化酶和被金属有机框架包裹的聚乳酸‑‑羟基乙酸共聚物纳米内核形成,所述金属有机框架由鞣酸和铁通过配位作用形成;所述靶向配体为透明质酸、合成多肽、叶酸修饰的亲水聚合物和核酸适配体中的一一种或多种。本发明的纳米反应器可主动靶向至肿瘤细胞,并催化产氧实现肿瘤原位供氧,清除谷胱甘肽和ATP从而抑制克服耐受,增强光动力治疗效率;其制备方法简单有效,有效避免了载体的毒性,载药量和修饰率高,可应用于制备肿瘤靶向药物。

traducir

COMPOSITIONS AND METHODS OF TREATMENT

NºPublicación: CN112770732A 07/05/2021

Solicitante:

蓝莓疗法有限公司

WO_2020008195_A1

Resumen de: WO2020008195A1

The present invention relates to compositions for use in the treatment of a dermatological condition, comprising a polymer capable of forming nanoparticles an anti-inflammatory and/or analgesic agent. The composition is particularly suited to the treatment of acne and/or atopic dermatitis. The invention also relates to novel uses of polyhexamethylene biguanide.

traducir

METHODS AND COMPOSITIONS OF OTC CONSTRUCTS AND VECTORS

NºPublicación: CN112771070A 07/05/2021

Solicitante:

西莱克塔生物科技公司

KR_20210032438_A

Resumen de: WO2020018583A1

Provided herein are methods and compositions related to nucleic acids encoding ornithine transcarbamylase (OTC), such as nucleic acids comprising an OTC codon- optimized sequence, as well as related vectors, such as AAV vectors. Also, provided are methods for administering AAV vectors that comprise a sequence that encodes an enzyme associated with an urea cycle disorder and an expression control sequence, in combination with synthetic nanocarriers coupled to an immunosuppressant.

traducir

VIRUCIDAL NANOPARTICLES AND USE THEREOF AGAINST INFLUENZA VIRUS

NºPublicación: CN112770780A 07/05/2021

Solicitante:

洛桑联邦理工学院

CA_3110766_A1

Resumen de: WO2020048976A1

The invention relates to virucidal nanoparticles comprising a trisaccharide moiety and use thereof against influenza virus.

traducir

一种复合纳米载药体系及其制备方法

Nº publicación: CN112755186A 07/05/2021

Solicitante:

南京邮电大学

Resumen de: CN112755186A

本发明公开了一种复合纳米颗粒载药体系及其制备方法,载药体系包括水凝胶,以及分散于水凝胶中的聚合物纳米颗粒和生物活性酶;所述生物活性酶具有降解肿瘤微环境细胞外基质的特性,所述聚合物纳米颗粒的表面负载有抗癌药物,并以聚苯胺颗粒为内核、以聚丙烯酸为外壳形成核壳结构。先合成带有光热升温、光声成像性能的聚丙烯酸聚苯胺核壳结构纳米颗粒,通过静电相互作用吸附抗癌药物,然后将复合纳米颗粒、胶原酶加入到两种带相反电荷的聚电解质水溶液中形成复合的可注射聚电解质水凝胶。本发明的复合纳米颗粒载药体系载药量高,可逐级释放胶原酶和复合聚苯胺纳米颗粒,实现光声成像介导的深度化疗‑光热联合治疗。

traducir

Página1 de 8 nextPage por página

punteroimgVolver